for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amarin Corporation plc (ADR)

AMRN.OQ

Latest Trade

22.45USD

Change

0.64(+2.93%)

Volume

1,171,256

Today's Range

21.75

 - 

22.50

52 Week Range

11.79

 - 

24.66

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
21.81
Open
21.86
Volume
1,171,256
3M AVG Volume
180.00
Today's High
22.50
Today's Low
21.75
52 Week High
24.66
52 Week Low
11.79
Shares Out (MIL)
358.91
Market Cap (MIL)
8,057.46
Forward P/E
-156.34
Dividend (Yield %)
--

Next Event

Half Year 2020 Amarin Corporation PLC Earnings Release

Latest Developments

More

Amarin Says Reduce-It USA Results Showed Robust Cardiovascular Risk Reductions Across A Variety Of Study Endpoints

Amarin Reports Qtrly Loss Per Share $0.01

Amarin Reports Q2 GAAP Loss Per Share Of $0.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amarin Corporation plc (ADR)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Industry

Biotechnology & Drugs

Contact Info

Gemini House, Bartholomews Walk

+353.1.6699020

http://www.amarincorp.com/

Executive Leadership

Lars G. Ekman

Independent Chairman of the Board

John F. Thero

President, Chief Executive Officer, Director

Michael Wayne Kalb

Chief Financial Officer, Senior Vice President, Assistant Secretary

Joseph T. Kennedy

Executive Vice President, General Counsel, Secretary, Strategic Initiatives

Stephen B. Ketchum

President - Research and Development, Senior Vice President, Chief Scientific Officer

Key Stats

2.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.2K

2019(E)

0.4K
EPS (USD)

2016

-0.410

2017

-0.250

2018

-0.390

2019(E)

-0.144
Price To Earnings (TTM)
--
Price To Sales (TTM)
22.15
Price To Book (MRQ)
13.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.08
LT Debt To Equity (MRQ)
1.49
Return on Investment (TTM)
-18.22
Return on Equity (TTM)
-11.77

Latest News

Latest News

FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa

A panel of experts to the U.S. FDA recommended allowing Amarin Corp Plc's fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa

A panel of experts to the U.S. FDA on Thursday recommended allowing Amarin Corp Plc's fish-oil derived drug to be used as add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

Amarin surges as fish-oil drug receives largely positive FDA review

Amarin Corp Plc's fish oil-derived drug received a largely positive review from FDA staffers on Tuesday, dispelling investor fears that the company's choice of placebo in its trial could challenge the approval of its potential blockbuster.

Shares of Amarin jump after FDA staff review on fish-oil drug

U.S. Food and Drug Administration staffers reviewing Amarin Corp Plc's fish oil-derived drug said on Tuesday the agency's tests were inconclusive on whether the use of mineral oil as placebo in the company's trial could have impacted results.

Amarin's Vascepa cuts occurrence of serious heart problems 30 percent: study

A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according...

BRIEF-Amarin Corporation Reports Q1 GAAP Loss Per Share $0.08

* REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin estimates net product revenue for Q1 to be about $43 mln

* AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES

BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE

* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS

BRIEF-Amarin Corporation Says ‍Ministry Of Public Health In Lebanon Approved Vascepa

* AMARIN CORPORATION PLC - MINISTRY OF PUBLIC HEALTH IN LEBANON HAS APPROVED VASCEPA

BRIEF-Amarin Reports Fourth Quarter Loss Of $0.08 Per Share

* AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

BRIEF-Amarin Prices Public Offering Of American Depositary Shares

* AMARIN PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Amarin Announces Proposed Public Offering Of American Depositary Shares

* AMARIN ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China

* AMARIN ANNOUNCES COMMENCEMENT OF VASCEPA CLINICAL DEVELOPMENT IN MAINLAND CHINA Source text for Eikon: Further company coverage:

BRIEF-Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​

* AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK

BRIEF-Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study

* AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations

BRIEF-Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

* Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

BRIEF-Amarin names Mark Salyer chief commercial officer

* Amarin appoints Mark W. Salyer to new position of chief commercial officer

BRIEF-Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned

* Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee

BRIEF-Amarin reports Q2 loss per share $0.05

* Amarin reports second quarter 2017 financial results and provides update on operations

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up